Sugi Predict

Sugi Predict / Compounds / SCHEMBL2172444

SCHEMBL2172444

SCHEMBL2172444

CCCC(NC(N)=O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 1/20 0.46
▸ CHRM1 P11229 1/20 0.44
▸ AKR1A1 P14550 1/20 0.44
▸ CHRM3 P20309 1/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ HTR2C P28335 1/20 0.44
▸ ADRA1A P35348 1/20 0.44
▸ HRH1 P35367 1/20 0.44
▸ DRD3 P35462 1/20 0.44
▸ SLC6A3 Q01959 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ NOD1 Q9Y239 4/20 0.43
▸ FOLH1 Q04609 4/20 0.42
▸ RIMKLA Q8IXN7 1/20 0.42
▸ NAALAD2 Q9Y3Q0 1/20 0.42
▸ MME P08473 1/20 0.42
▸ CAD P27708 1/20 0.42
▸ TGFBR1 P36897 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3282950 1.00 FPR2 (0.46) FPR2CHRM1AKR1A1CHRM3HTR2A
Hydrochloric Acid SCHEMBL32661728 0.98 FPR2 (0.45) FPR2CHRM1AKR1A1CHRM3HTR2A
SCHEMBL3282650 0.88 NOD1 (0.53) HDAC2NOD1FOLH1MMESLC1A3
SCHEMBL11254859 0.88 NOD1 (0.53) HDAC2NOD1FOLH1MMESLC1A3
SCHEMBL9953741 0.84 CAD (0.43) FPR2CHRM1AKR1A1CHRM3HTR2A
SCHEMBL8506897 0.84 NOD1 (0.58) NOD1GRIK1GRIK2SLC6A5MAPT
SCHEMBL2107300 0.83 FPR2 (0.44) FPR2CHRM1AKR1A1CHRM3HTR2A
SCHEMBL30678658 0.83 FPR2 (0.44) FPR2CHRM1AKR1A1CHRM3HTR2A
SCHEMBL18095235 0.83 CAD (0.40) FPR2CHRM1AKR1A1CHRM3HTR2A
Hydrochloric Acid SCHEMBL22534231 0.83 CAD (0.42) FPR2CHRM1AKR1A1CHRM3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260112616-A1 ADVANCED ELECTROLYTE SYSTEMS WITH SPECIALIZED ADDITIVES FOR IMPROVING PERFORMANCE OF LITHIUM-SULFUR BATTERIES LYTEN INC (US) 2026-04-23 — — US disclosed
US-20260027220-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2026-01-29 — — US disclosed
US-20240200049-A1 COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS YALE UNIVERSITY 2024-06-20 — — US disclosed
WO-2024012541-A1 ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF 百奥泰生物制药股份有限公司 2024-01-18 — — WO disclosed
WO-2024002042-A1 METHOD FOR TREATING SOLID TUMOR 百奥泰生物制药股份有限公司 2024-01-04 — — WO disclosed
WO-2023232080-A1 ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF 百奥泰生物制药股份有限公司 2023-12-07 — — WO disclosed
WO-2023198079-A1 METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR 百奥泰生物制药股份有限公司 2023-10-19 — — WO disclosed
WO-2023174511-A1 ENZYMATIC METHOD FOR THE PRODUCTION OF L-GLUFOSINATE P-ESTERS EVONIK OPERATIONS GMBH (DE) 2023-09-21 — — WO disclosed
CN-116715635-A Synthesis process of 5-n-propyl hydantoin 河北鑫淘沅医药科技有限公司 2023-09-08 — — CN disclosed
CN-116715635-A Synthesis process of 5-n-propyl hydantoin 河北鑫淘沅医药科技有限公司 2023-09-08 — — CN disclosed
WO-2023061457-A1 ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF 百奥泰生物制药股份有限公司 2023-04-20 — — WO disclosed
US-20200283482-A1 BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF Bicyclerd Limited (GB) 2020-09-10 — — US disclosed
US-20200190500-A1 COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS YALE UNIVERSITY 2020-06-18 — — US disclosed
CN-109476648-A Sevelamer antibody-drug conjugates and methods of use 豪夫迈·罗氏有限公司 2019-03-15 — — CN disclosed
US-20160355802-A1 Compositions and Methods Of Use Thereof For Making Polypeptides With Many Instances Of Nonstandard Amino Acids YALE UNIVERSITY 2016-12-08 — — US disclosed
EP-2569000-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY Indiana University Research and Technology Corporation (US) 2013-03-20 — — EP disclosed
WO-2011143209-A1 GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-11-17 — — WO disclosed
EP-2346870-A1 18F-LABELLED FOLATES AS PET RADIOTRACERS Merck & Cie (CH) 2011-07-27 — — EP disclosed
WO-2010040854-A1 18F-LABELLED FOLATES AS PET RADIOTRACERS MERCK EPROVA AG (CH) 2010-04-15 — — WO disclosed
US-6277991-B1 FOR TREATMENT OF MIGRAINE, NON-INSULIN DEPENDENT DIABETES MELLITUS, SEPSIS, INFLAMMATION, INCONTINENCE, VASOMOTOR DISTURBANCES SUCH AS HOT FLUSHES OR HOT FLASHES NOVO NORDISK A/S (DK) 2001-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027220-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF EPHA2, EPHA1, EPHB1 FPR2 1591/4885CHRM1 2834/4885AKR1A1 633/4885
US-20260112616-A1 ADVANCED ELECTROLYTE SYSTEMS WITH SPECIALIZED ADDITIVES FOR IMPROVING PERFORMANCE OF LITHIUM-SULFUR BATTERIES MEF2D, LEF1, KCNN2 FPR2 3018/4885CHRM1 3437/4885AKR1A1 3392/4885
US-20200283482-A1 BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF PRRC2A, GRPR, QRFPR FPR2 51/4885CHRM1 3705/4885AKR1A1 4067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.